All In Biotech

BLA 103705 · Genentech

Rituxan

Rituximab · Intravenous · CD20-directed Cytolytic Antibody

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Nov 26, 1997

Approved uses

18

Original approval plus efficacy supplements

Registered trials

2,564

526 Phase 3, 340 recruiting

FAERS reports

214,105

191,594 serious, 37,921 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Fatal infusion-related reactions within 24 hours of RITUXAN infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue RITUXAN infusion for severe reactions ( 5.1 ). Severe mucocutaneous reactions, some with fatal outcomes ( 5.2 ). Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death ( 5.3 ). Progressive multifocal leukoencephalopathy (PML) resulting in death ( 5.4 ). Infusion-Related Reactions RITUXAN administration...

What it is approved for

From the label in effect Jan 6, 2025.

RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe...

Mechanism: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 2, 2021 Supplement 5465 · Efficacy · priority review OrphanLabelMedication GuideLetter
  • Aug 28, 2020 Supplement 5460 · Efficacy LetterLabel
  • Sep 27, 2019 Supplement 5457 · Efficacy · priority review OrphanLetterLabelMedication Guide
  • Jan 25, 2019 Supplement 5454 · Efficacy OrphanLabelLetter
  • Oct 18, 2018 Supplement 5451 · Efficacy OrphanLabelLetter
  • Jun 7, 2018 Supplement 5450 · Efficacy · priority review OrphanLabelLetter
  • Oct 19, 2012 Supplement 5367 · Efficacy OrphanLabelLetter
  • Apr 19, 2011 Supplement 5344 · Efficacy · priority review OrphanReviewLetterLabel
  • Jan 28, 2011 Supplement 5332 · Efficacy OrphanLetterLabel
  • Feb 18, 2010 Supplement 5312 · Efficacy · priority review OrphanLabelLetter
  • Feb 18, 2010 Supplement 5311 · Efficacy · priority review OrphanLabelLetter
  • Oct 16, 2009 Supplement 5299 · Efficacy LabelLetter
  • Jan 25, 2008 Supplement 5256 · Efficacy LabelLetter
  • Sep 29, 2006 Supplement 5231 · Efficacy · priority review OrphanLabel
  • Sep 29, 2006 Supplement 5230 · Efficacy · priority review OrphanLabelLetter
  • Feb 28, 2006 Supplement 5211 · Efficacy · priority review LetterLabel
  • Feb 10, 2006 Supplement 5209 · Efficacy · priority review OrphanLabel
  • Nov 26, 1997 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewOther Important Information from FDA
2 products under this application
  • RITUXAN · RITUXIMAB 500MG/50ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • RITUXAN · RITUXIMAB 100MG/10ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rituximab" as an intervention, any sponsor and status, largest first.

All 2,564 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use41,722
  • drug ineffective34,408
  • rheumatoid arthritis20,327
  • pain17,935
  • fatigue17,483
  • rash13,683
  • arthralgia13,466
  • pneumonia13,256
  • infusion related reaction12,870
  • drug intolerance12,675
  • joint swelling12,000
  • pyrexia11,912

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004508
2005739
2006724
20071,256
20081,417
20092,038
20102,486
20113,186
20124,694
20134,805
20145,019
20155,951
20166,768
201711,206
201812,326
201914,980
202020,539
202118,597
202221,328
202320,221
202424,171
202518,885
202612,260

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rituxan (Rituximab)

2024 spending

$38.7M

Beneficiaries

1,499

3,244 claims

Per beneficiary

$25,831

$91.19 per unit

View as table
YearSpending
2020$54,977,642
2021$46,933,066
2022$46,055,636
2023$39,322,014
2024$38,719,960

Part B: Rituxan (Rituximab) · HCPCS J9312

2024 spending

$437M

Beneficiaries

22,261

65,209 claims

Per beneficiary

$19,630

2024 ASP limit $78.26 per unit

View as table
YearSpending
2020$1,295,906,200
2021$765,560,206
2022$579,169,245
2023$483,730,047
2024$436,980,635

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,601 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.